Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion
Portfolio Pulse from
Intellia Therapeutics (NTLA) is facing a class action lawsuit alleging false and misleading statements about its drug development program, particularly regarding NTLA-3001. The lawsuit claims the company misrepresented the viability of its viral-based editing program and ultimately discontinued the NTLA-3001 project, causing a 15% stock price drop on January 9, 2025.
April 10, 2025 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit alleges company misled investors about NTLA-3001 drug development, potentially impacting investor confidence and stock performance.
The lawsuit alleges systematic misrepresentation of drug development capabilities, which could damage investor trust, lead to potential financial penalties, and negatively impact stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100